UPDATE: The blood tests are in, and it looks like the women instructed to take the pills were not popping them. Only a quarter of those who got infected had any Truvada in their blood. This suggests that the problem isn't the drug's effectiveness, but rather compliance on the part of the population. What’s the News: A much-anticipated trial in African women of an HIV drug found to be effective in preventing infection in men has washed out—researchers announced today that women taking Truvada were no more likely to evade HIV infection than women taking a placebo. The result is especially disappointing because Truvada, which is an oral pill combining two drugs, emtricitabine and tenofovir disoproxil fumarate, has been shown to be 90% effective in preventing infection in gay men who took it religiously.
What’s the Context:
Truvada, made by Gilead Sciences, is also used to treat patients with HIV, ...
